Please go ahead. Thank you, Paul, and good morning, everybody. Thanks for joining us for Eli Lilly and company's Q3 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations.

Please go ahead. Thank you, Paul, and good morning, everybody. Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings call. I'm Joe Fletcher, Senior Vice President of Investor Relations.

(Bloomberg) -- Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start ... metabolic ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost any ...

Eli Lilly and Company Stock Down 1.3 % Eli Lilly and Company stock opened at $891.66 on Friday. The firm has a market cap of $847.44 billion, a P/E ratio of 131.32, a P/E/G ratio of 2.79 and a ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other S&P 500 stocks. As per AXA Investment Managers, the US dominated financial markets this ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Conditions are getting a bit more challenging for the drugmaker.

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.